PRINCETON, N.J., Nov. 1 /PRNewswire-FirstCall/ -- Cytogen Corporation today announced that Michael D. Becker, president and chief executive officer, will present at the Rodman and Renshaw 8th Annual Healthcare Conference, which is being held November 6-8 in New York City. Cytogen’s presentation is scheduled for 10:35 a.m. EST on Tuesday, November 7, 2006. The presentation will also be available as a webcast that interested parties can access from the Investor Relations page at http://www.cytogen.com.
About Cytogen
Founded in 1980, Cytogen is a biopharmaceutical company dedicated to advancing the care of cancer patients by acquiring, developing, and commercializing innovative pharmaceutical products. The Company’s specialty sales force currently markets QUADRAMET(R), PROSTASCINT(R), and SOLTAMOX(R) to the U.S. oncology market. QUADRAMET is approved for the treatment of pain in patients whose cancer has spread to the bone, PROSTASCINT is a PSMA-targeting monoclonal antibody-based agent to image the extent and spread of prostate cancer, and SOLTAMOX is the first liquid hormonal therapy approved in the U.S. for the treatment of breast cancer in adjuvant and metastatic settings. In early 2007, Cytogen plans to introduce its fourth marketed product to the U.S. market, CAPHOSOL(R), a prescription medical device for the treatment of oral mucositis and dry mouth. The Company is also developing CYT-500, a third- generation radiolabeled antibody to treat prostate cancer. Cytogen’s product- focused strategy focuses on attaining sustainable growth through clinical, commercial, and strategic initiatives.
Cytogen Corporation
CONTACT: Investors contact: Susan Mesco, Cytogen Corporation,+1-609-750-8213
Web site: http://www.cytogen.com/
